1 citations
,
April 2023 in “Heliyon” Disitamab vedotin and gemcitabine effectively treated bladder cancer without major side effects.
2 citations
,
August 2002 in “British Journal of Ophthalmology” Tangent screens help detect visual field defects from vigabatrin.
44 citations
,
April 2006 in “Expert opinion on drug safety” Gefitinib can cause skin problems, diarrhea, and nausea, but rarely causes severe lung disease or hair loss.
22 citations
,
April 1998 in “Dermatologic Clinics” Interferons are effective for some skin conditions and cancers, but can have side effects and need more research for optimal use.
1 citations
,
July 2016 in “Dermatologic surgery” March 2022 in “Oncology Times” Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.
April 2023 in “Journal of Investigative Dermatology” ALRN-6924 can protect hair follicles from chemotherapy damage by temporarily stopping cell division.
11 citations
,
December 2013 in “Clinical and Experimental Dermatology” Sorafenib often causes skin side effects, indicating effective cancer treatment.
2 citations
,
September 2018 in “JAAD case reports” A rare type of skin cancer with mucosal involvement was partially treated but eventually relapsed.
August 2021 in “Acta Haematologica Polonica” Folliculotropic mycosis fungoides has a worse prognosis than other types, with survival rates varying significantly based on subtype and organ involvement.
75 citations
,
June 2007 in “Journal of Biological Chemistry” MT-DADMe-ImmA can selectively kill head and neck cancer cells without harming normal cells.
14 citations
,
August 2017 in “International Journal of Immunopathology and Pharmacology” Photodynamic therapy improved skin issues from sorafenib when other treatments failed.
January 2004 in “Indian Journal of Nephrology” 8 citations
,
January 2020 in “Evidence-based Complementary and Alternative Medicine” Cinobufacin with chemotherapy improves treatment response and quality of life in advanced breast cancer patients while reducing some side effects.
21 citations
,
August 2002 in “British Journal of Ophthalmology” Drug misuse can cause serious eye infections and other severe side effects.
2 citations
,
January 2013 in “Iraqi journal of Medical Sciences”
April 2016 in “Journal of Investigative Dermatology” Mefloquine, an antimalarial drug, is effective in killing melanoma cells resistant to other treatments by causing lethal stress in the cells.
Flutamide helps with prostate cancer and some skin conditions but can harm the liver.
1 citations
,
September 2001 in “PubMed” ONO-3403 effectively reduces mouse skin tumor growth without side effects.
1 citations
,
October 2025 in “Scientific Reports” Sonidegib and vismodegib have different side effects and reporting patterns.
15 citations
,
May 1966 in “The Journal of Urology” A woman developed severe bladder inflammation after cancer treatment with Cytoxan.
12 citations
,
June 2016 in “Clinical and Molecular Hepatology” Mycophenolate mofetil can effectively treat autoimmune hepatitis when standard drugs fail.
3 citations
,
May 2025 in “Frontiers in Pharmacology” Vismodegib can cause muscle spasms, taste changes, hair loss, fatigue, weight loss, and possibly new issues like skin cancer, dehydration, and swallowing problems, needing close monitoring.
6 citations
,
March 2014 in “Annals of Pharmacotherapy” A woman's hair loss was probably caused by the antifungal drug anidulafungin.
39 citations
,
May 2006 in “Molecular Plant-Microbe Interactions” Fusaric acid may help control Orobanche ramosa by activating plant defenses.
March 2005 in “Journal of The American Academy of Dermatology” Mycophenolate mofetil improved skin condition in a man with nephrogenic fibrosing dermopathy.
April 2017 in “The journal of investigative dermatology/Journal of investigative dermatology” Most patients experienced mild to moderate skin problems during a trial for a desmoid tumor treatment.
1108 citations
,
January 2018 in “Dalton transactions” Platinum-based chemotherapy drugs can cause many severe side effects, often requiring dose reductions and additional medications to manage.
39 citations
,
September 2015 in “Clinical Therapeutics” Teriflunomide effectively reduces relapse rates and disease progression in multiple sclerosis but is not safe for use during pregnancy.